And a post last night on Truth Social, President Trump shared a video highlighting the health benefits of hemp hemp derived cannabid oil or CBD. Now, Tillray, Canopy Growth, Aurora, all jumping double digits. The video said it could quote, "Revolutionize senior health care, serving as a alternative to costly prescription drugs." Of course, another area of the president's focus.Now, this isn't Trump's first move in cannabis, though. Back in the 2018 Farm Bill, hemp derived products like CBD were legalized. A ...

Core Viewpoint - Cannabis stocks experienced significant gains following President Donald Trump's promotion of a video advocating for the inclusion of cannabidiol (CBD) under Medicare coverage [1][6]. Group 1: Stock Performance - Tilray Brands surged nearly 20% and was up 36% after market open [1]. - Canopy Growth jumped about 20%, while Cronos Group rose 13% [1]. - Aurora Cannabis climbed 13.3%, and Trulieve Cannabis spiked almost 20% [1]. - Green Thumb Industries, Curaleaf Holdings, and Innovative Industrial Properties also saw considerable share price increases [3]. Group 2: Video Promotion and Content - The video produced by The Commonwealth Project features Trump and a narrator advocating for wider access to CBD for seniors [6][9]. - The narrator claims that hemp-derived CBD can significantly improve the quality of life for older adults [7][10]. - The video suggests that CBD can help restore the endocannabinoid system and assist with pain, sleep, and stress [10]. Group 3: Regulatory Context - Trump previously indicated he was considering reclassifying marijuana as a less dangerous substance, although no action has been taken yet [8]. - The timing of the video promotion coincides with Congress deliberating on tightening hemp regulations, with some Republicans advocating for stricter limits on CBD products containing trace amounts of THC [8].

Core Viewpoint - President Donald Trump's recent video on Truth Social has reignited interest in cannabis, particularly its potential health benefits and the possibility of changes in federal drug policy [1][2]. Group 1: Health Benefits of Cannabis - The video, produced by The Commonwealth Project, advocates for CBD to be covered under Medicare, labeling it as "the most important senior health initiative of the century" [2]. - It claims that CBD could slow disease progression and serve as an alternative to many prescription drugs for older adults, potentially saving the healthcare system $64 billion annually if cannabis is fully integrated [2]. Group 2: Federal Policy Implications - Trump's video follows earlier comments indicating that his administration is considering reclassifying cannabis at the federal level, which could lead to reduced criminal penalties and eased operational restrictions for cannabis businesses [2]. Group 3: Market Reaction - The announcement led to a significant rally in cannabis stocks, with Canopy Growth Corp. rising 15% and Tilray Brands, Inc. surging 35% [3]. - Other companies such as Cronos Group, Inc., SNDL Inc., and Aurora Cannabis, Inc. also saw increases of over 20% [3]. - The AdvisorShares Pure US Cannabis ETF experienced a nearly 20% increase, reflecting the overall positive market sentiment towards the cannabis sector [4].

Core Insights - A social media post by US President Donald Trump suggested potential health benefits from cannabidiol (CBD) use, leading to a rise in shares of cannabis companies in early premarket trading [1] Group 1 - The cannabis industry experienced a positive market reaction following Trump's comments, indicating increased investor interest [1] - The mention of health benefits from CBD by a high-profile figure like the President may enhance public perception and acceptance of cannabis products [1]

By signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox. ...

Core Insights - Canopy Growth Corporation (NASDAQ:CGC) reported Q1 FY2026 net revenue of $72.1 million, representing a 9% year-over-year increase driven by a 13% rise in medical cannabis sales and a 43% increase in adult-use cannabis sales in Canada [1] - The company experienced a decline in consolidated gross margin from 35% to 25% due to lower high-margin sales in Poland and a shift towards higher-cost manufactured products [1] - The net loss from continuing operations decreased by 21% to $23 million, while SG&A expenses also fell by 21% as part of $17 million in annualized cost savings [1] Financial Performance - Q1 FY2026 net revenue: $72.1 million, up 9% year-over-year [1] - Medical cannabis sales increased by 13% [1] - Adult-use cannabis sales in Canada rose by 43% to $27 million [1] - International cannabis revenue increased by 5% to $8.8 million [1] - Storz & Bickel vaporizer revenue decreased by 25% to $15.1 million [1] - Consolidated gross margin declined from 35% to 25% [1] - Net loss from continuing operations fell by 21% to $23 million [1] - SG&A expenses decreased by 21% [1] - Cash and short-term investments rose to $144 million [1] Strategic Outlook - CEO Luc Mongeau highlighted significant share growth in cannabis markets with high demand [2] - Interim CFO Tom Stewart noted improving gross margins as a key target for FY2026 [2] - A new Storz & Bickel vaporizer is set to be introduced later in 2025 [2] - The company anticipates that automation and increased PRJ production will enhance margins in the second half of FY2026 [2]

Industry Overview - The Canadian cannabis sector is crucial for investors looking to tap into the expanding U.S. marijuana market, which generated over $33 billion in sales in 2024 and is projected to exceed $50 billion by 2030 due to increasing state-level legalization and consumer demand [1][3] - Recent discussions around federal reform and rescheduling cannabis could benefit Canadian companies with U.S. partnerships or expansion plans, making them attractive to investors [1][3] Company Highlights - **Tilray Brands, Inc. (TLRY)**: - Operates in cultivation, processing, and distribution across Canada, Europe, and the U.S., focusing on hemp-derived beverages and wellness products, reaching about 1,000 retail stores [5][7] - Reported annual revenue of approximately $821 million with a gross profit of around $240 million, but net income remains negative with losses exceeding $2 billion [7] - **Canopy Growth Corporation (CGC)**: - One of the largest cannabis companies in Canada, with a strong presence in the U.S. through brands and subsidiaries rather than direct dispensary ownership [8][10] - Achieved year-over-year revenue growth of about 9%, but gross margin fell to 25% from 35% a year earlier, indicating financial strain [10] - **Village Farms International, Inc. (VFF)**: - Transitioned from agricultural production to cannabis, operating one of the largest cannabis greenhouse facilities in Canada with over 2.2 million square feet [12][14] - Reported annual revenue of about $336 million, a 17% increase from the previous year, but posted a net loss of approximately $36 million [14] Strategic Focus - Tilray is diversifying through beverages and wellness products, while Canopy is focusing on cost-cutting and U.S. brand partnerships [15] - Village Farms emphasizes efficiency and international expansion, positioning itself as one of the lowest-cost producers in Canada [14][15] Market Outlook - The Canadian cannabis sector faces challenges from oversupply and regulatory uncertainty, but leading companies are adapting their strategies to remain competitive [15][16] - September 2025 is seen as a critical period for the sector, with investors closely monitoring earnings, cost controls, and expansion efforts [16]

Core Viewpoint - Canopy Growth Corporation has launched a new at-the-market equity program to raise up to $200 million in common shares, aimed at supporting strategic investments and working capital [1][2]. Group 1: Equity Program Details - The new equity program allows for the issuance and sale of up to $200 million in common shares across U.S. and Canadian markets, with Canadian sales capped at $50 million [2]. - The program is governed by an equity distribution agreement dated August 29, 2025, with BMO Nesbitt Burns Inc. and BMO Capital Markets Corp. as agents [3]. - The program will remain active until June 5, 2027, or until the full $200 million is raised, with the Canadian portion ending earlier on July 5, 2026, or upon reaching its $50 million cap [3]. Group 2: Company Overview - Canopy Growth Corporation operates in the cannabis industry, producing and selling cannabis, hemp, and related products across Canada, Germany, and Australia [4]. - The company operates through four segments, including Canada Cannabis and International Markets, offering a variety of products such as dried flower, pre-rolls, edibles, vapes, oils, and concentrates [4]. - Canopy Growth markets its products under multiple brands, including Tweed, 7ACRES, Spectrum Therapeutics, Storz & Bickel, Wana, and DOJA [4].

the "Company†), a world-leading manufacturer of high-end, medically certified cannabis vaporizers and a subsidiary of Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC), today unveiled the VEAZY— an accessible new addition to its premium portfolio, extending the Company's precision engineering to a broader audience. The VEAZY delivers an uncompromising solution, designed to be as approachable as it is easy t. TUTTLINGEN, Germany--(BUSINESS WIRE)--STORZ & BICKEL GmbH ("STORZ & BICKEL†or ...

Industry Overview - The Canadian cannabis sector is gaining investor attention as the U.S. market approaches broader reform, with the U.S. cannabis market projected to reach approximately $38.5 billion in 2024 and grow at a CAGR of 11-12% through the late 2020s [1][3] - Legislative changes in the U.S., such as Delaware's adult-use cannabis sales starting August 1, 2025, and potential federal rescheduling of marijuana, are creating strong thematic tailwinds for Canadian cannabis stocks with U.S. exposure [1][3] Company Highlights Tilray Brands (TLRY) - Tilray has established a strong global identity by combining cannabis, wellness, and beverages, significantly expanding its U.S. footprint through acquisitions [4][6] - The company reported record revenue exceeding $820 million for fiscal 2025, with gross margins averaging around 40%, showcasing strong cost management [8][9] - Tilray's strategic pivot into hemp-based beverages and wellness products allows it to build a presence in the U.S. market despite federal restrictions [10][7] Canopy Growth Corporation (CGC) - Canopy Growth is recognized as a leading cannabis company in Canada, with ambitions to enter the U.S. market through strategic partnerships and acquisitions, notably its option to acquire Acreage Holdings [10][12] - The company generated nearly $300 million in revenue but reported a net loss exceeding $650 million, highlighting ongoing profitability challenges [14][15] - Canopy's U.S. strategy is designed to unlock value upon legalization, with a strong brand portfolio and rights to Acreage Holdings representing potential growth [16] Village Farms International (VFF) - Village Farms operates in both agriculture and cannabis, leveraging its expertise in greenhouse cultivation to strengthen its cannabis operations in Canada [18][19] - The company reported net income above $25 million in 2025, with adjusted EBITDA reaching nearly 30% of total sales, demonstrating strong profitability and revenue growth [20] - Village Farms' focus on cultivation efficiency and vertical integration has allowed it to achieve profitability, distinguishing it from many cannabis peers [20][21] Conclusion - Tilray, Canopy Growth, and Village Farms each demonstrate unique strategies for growth and financial improvement in the evolving cannabis landscape [21] - These companies are well-positioned to capitalize on potential U.S. legalization and changing market dynamics, offering various investment opportunities [21]